Neuphoria Therapeutics (NEUP) investor group cuts reported stake to 4.23%
Rhea-AI Filing Summary
Neuphoria Therapeutics Inc. shareholder group led by Coastlands Capital LP and Matthew D. Perry reports beneficial ownership of 228,594 shares of common stock. Based on 5,404,551 shares outstanding as of May 14, 2026, this represents 4.23% of the company’s common stock.
The reporting persons hold no sole voting or dispositive power, but have shared voting and shared dispositive power over all 228,594 shares. They state that the securities were not acquired to change or influence control of Neuphoria Therapeutics. This Amendment No. 1 is described as an exit filing, as the group no longer beneficially owns more than 5% of any class of the issuer’s securities.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 228,594 shares
Ownership percentage: 4.23%
Shares outstanding: 5,404,551 shares
+4 more
7 metrics
Beneficially owned shares
228,594 shares
Shares of Neuphoria Therapeutics common stock reported as beneficially owned by each reporting person
Ownership percentage
4.23%
Percent of Neuphoria Therapeutics common stock class beneficially owned by each reporting person
Shares outstanding
5,404,551 shares
Common stock issued and outstanding as of May 14, 2026 used for ownership calculation
Sole voting power
0 shares
Each reporting person’s sole power to vote or direct the vote of NEUP shares
Shared voting power
228,594 shares
Each reporting person’s shared power to vote or direct the vote of NEUP shares
Sole dispositive power
0 shares
Each reporting person’s sole power to dispose or direct disposition of NEUP shares
Shared dispositive power
228,594 shares
Each reporting person’s shared power to dispose or direct disposition of NEUP shares
Key Terms
beneficial ownership, shared voting power, shared dispositive power, Schedule 13G, +2 more
6 terms
beneficial ownership financial
"The calculation of the beneficial ownership of the Reporting Persons is based on 5,404,551 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Schedule 13G regulatory
"Each reporting person also disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Rule 13d-3 regulatory
"it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
exit filing regulatory
"This Amendment No. 1 constitutes an exit filing for the Reporting Persons"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership level in Neuphoria Therapeutics (NEUP) is reported in this Schedule 13G/A?
The filing reports that the Coastlands group and Matthew D. Perry beneficially own 228,594 shares of Neuphoria Therapeutics common stock, representing 4.23% of the class based on 5,404,551 shares outstanding as of May 14, 2026.
Who are the reporting persons in the Neuphoria Therapeutics (NEUP) Schedule 13G/A?
The reporting persons are Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry. They file jointly, each disclaims group status and beneficial ownership beyond their pecuniary interest.
Does the Coastlands group still own more than 5% of Neuphoria Therapeutics (NEUP)?
No. The filing states this Amendment No. 1 is an exit filing because the reporting persons no longer beneficially own more than 5% of any class of Neuphoria Therapeutics’ securities, with their stake now at 4.23%.
Is the Coastlands group seeking to influence control of Neuphoria Therapeutics (NEUP)?
The signatories certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of Neuphoria Therapeutics, other than activities solely related to a nomination under Item 11.